Navigation Links
Cipla Launches the World's First Generic Pirfenidone in India, Giving Hope to Sufferers of IPF (Idiopathic Pulmonary Fibrosis)

Cipla Launches the World's First Generic Pirfenidone in India, Giving Hope to... -- MUMBAI, India, October 20, 2010 /PRNewswire-FirstCall/ --

Advanced Search Search

  1. Send a release
  2. Member sign in
  3. Become a member
  4. For journalists
  5. Global sites
PR Newswire: news distribution, targeting and monitoring
  1. Products & Services
  2. Knowledge Center
  3. Browse News Releases
  4. Contact PR Newswire
Health Care & Hospitals, Medical Equipment, Medical Pharmaceuticals, New Products & Services, Clinical Trials & Medical Discoveries Click to view news release full screen  

Cipla Launches the World's First Generic Pirfenidone in India, Giving Hope to Sufferers of IPF (Idiopathic Pulmonary Fibrosis)


MUMBAI, India, October 20, 2010 /PRNewswire-FirstCall/ -- Cipla, among the world's leading generic pharmaceutical companies, has introduced Pirfenidone in India under the brand name Pirfenex, for the treatment of IPF. A chronic progressive form of lung disease, IPF has average survival rates as low as 3-5 years which is less than many cancers. Till now there is no approved treatment for IPF. Pirfenidone is a novel anti-fibrotic drug which through clinical trials has shown to slow down progression of this terminal disease and stabilize lung function.

Cipla's technical prowess along with leadership in terms of range of drugs and therapeutic categories in the respiratory segment, is leading the fight to provide world class affordable treatment for patients with orphan diseases. Commenting on the launch, Dr. J Gogtay, Medical Director, Cipla, said, "The launch of Pirfenex is a significant step forward. With increased availability and affordability, Pirfenex could now offer hope to those afflicted with this condition."

Pirfenex will be manufactured at Cipla's state-of-the-art manufacturing facility at Himachal Pradesh, India which is approved by WHO, MCC -South Africa and TGA - Australia.

In addition to the launch, Cipla will host and disseminate a series of lectures on IPF to physicians in India and across the world. Addressing the delegates Prof Luca Richeldi, Director, Center for Rare Lung Diseases, University of Modena and Reggio Emilia, Italy, said, "Patients affected by IPF have a distinctively poor prognosis, and until now no drugs have been approved to treat IPF. Pirfenidone represents the first concrete chance of slowing down disease progression. The effect on increasing progression free survival, as showed in three combined studies, coupled with an acceptable safety profile, opens up a new path for better management of IPF."

Last year Cipla launched the world's first generic Bosentan, for the treatment of Pulmonary Arterial Hypertension. With the launch of Pirfenex, Cipla reaffirms its leadership in the respiratory arena with products and services in 8 therapeutic areas viz. asthma, COPD, allergic rhinitis, respiratory infections, pulmonary and critical care, pulmonary arterial hypertension, lung cancer and IPF.

About Cipla:

Cipla laid foundations for the Indian pharmaceutical industry back in 1935 with the vision to make India self-reliant in healthcare. Over the years Cipla has emerged as one of the most respected names not just in India but worldwide. Its state of the art R&D centre has given the country and the world many firsts. This includes the revolutionary AIDS cocktail for less than a dollar a day. With over 40 manufacturing units across the country, Cipla manufactures over 1200 products in 80 therapies.

With a turnover of over US $ 1 billion, Cipla serves doctors and patients in over 180 countries. It has earned a name for maintaining one global standard across all its products and services. Cipla continues to support, improve and save millions of lives with its high-quality drugs and innovative devices. (

Media Contact: Antara +91-99-67516441/+91-22-23025813

SOURCE Cipla Limited
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Frost & Sullivan Award Underlines Cipla Medpros Status as Company of the Year in the South African Generic Pharmaceutical Market
2. Stereotaxis Launches the Odyssey Interventional Network for Superior Online Cardiovascular Education and Training
3. Brazoria County Launches Free Prescription Discount Card
4. BioMolecular Therapeutics, a New Global Player in RNAi Therapeutics, Launches Company and Adds Key Advisors
5. endpoint Launches PULSE 2.0 Allowing Clinical Research Teams to Save Additional Time and Money By Rapidly Deploying Studies With Custom Reporting
6. Aircraft Medical Launches Worlds First Low Cost Video Laryngoscope
7. Cantel Medical Corp. Launches New Medical Face Mask Addressing Issue of Fit
8. New England Biolabs Launches a Suite of Innovative Tools to Advance Epigenetics Research, Including PCR-Based Assay to Identify and Quantitate 5-hmC in Epigenome
9. International Medical News Group Relaunches Internal Medicine News Digital Network and Hospitalist News Digital Network
10. Physicians Interactive Launches Partnership with SampleMD to Expand Sampling Options for Clinicians and Reduce Costs for Patients
11. Terso Solutions Launches New RFID-Enabled Freezer for Inventory Management in Hospitals, Research Labs, Manufacturers and Distributors, and Crime Labs
Post Your Comments:
(Date:11/24/2015)... Nov. 24, 2015  In the pharmaceutical industry, companies ... effort to quickly uncover new insights, tactics and strategies ... --> --> However, organizations often find ... project and ensure that all rules and regulations are ... Another major barrier to efficiently launching market research projects ...
(Date:11/24/2015)... NEWPORT NEWS, Va. , Nov. 24, 2015 /PRNewswire/ ... that they have signed an agreement for DILON to ... select geographies across the globe. The signing of this distribution ... GE,s Discovery NM750b Molecular Breast Imaging system and is ... ways to provide better healthcare solutions for clinicians and ...
(Date:11/24/2015)... Nov. 24, 2015   HeartWare International, Inc . ... miniaturized circulatory support technologies that are revolutionizing the treatment ... Chief Executive Officer Doug Godshall is scheduled ... Annual Healthcare Conference on December 1, 2015 at 3:00 ... in New York . ...
Breaking Medicine Technology:
(Date:11/25/2015)... ... November 25, 2015 , ... ... lower prices in an early celebration of the early holiday shopping season. Starting ... $29.95 each (normally $33.95 ea). Black Friday promotional pricing is in addition to ...
(Date:11/24/2015)... PA (PRWEB) , ... November 24, 2015 , ... ... now certified to offer their patients the many benefits of the revolutionary BIOLASE ... the sharp cutting and scraping tools traditionally used by a dentist in ...
(Date:11/24/2015)... ... November 24, 2015 , ... New patients who wish to seek treatment ... dental implants at her Mississauga, ON practice. Dr. Williams has been providing dental ... dental implants. , Missing teeth can lead to a variety of complications if ...
(Date:11/24/2015)... , ... November 24, 2015 , ... Charitable giving is ... donations are made in the last five weeks of the year totalling over $358 ... in 2012 to connect the nation’s charities with those individuals who want to “give ...
(Date:11/24/2015)... , ... November 24, 2015 , ... In an ... restrictions and variables that determine which patients are or are not eligible for bariatric ... have a BMI over 40, are more than 100 pounds overweight, or have a ...
Breaking Medicine News(10 mins):